Kathleen Gallagher
Corporate Officer/Principal bei AVIDITY BIOSCIENCES, INC.
Aktive Positionen von Kathleen Gallagher
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AVIDITY BIOSCIENCES, INC. | Corporate Officer/Principal | - | - |
Investor Relations Kontakt | 01.04.2021 | - | |
Public Communications Contact | 01.04.2021 | - |
Karriereverlauf von Kathleen Gallagher
Ehemalige bekannte Positionen von Kathleen Gallagher
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Public Communications Contact | 01.01.2003 | 01.10.2016 |
AKCEA THERAPEUTICS, INC. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - |
Ausbildung von Kathleen Gallagher
Boston University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Public Communications Contact | 3 |
Investor Relations Contact | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
AVIDITY BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Kathleen Gallagher
- Erfahrung